Document is current
Any future updates will be listed below
-
Authors
Velilla, José A. https://orcid.org/0000-0002-1282-4467
Volpe, Matthew R. https://orcid.org/0000-0002-0104-2929
Kenney, Grace E. https://orcid.org/0000-0002-9579-3351
Walsh, Richard M. Jr https://orcid.org/0000-0002-8939-8988
Balskus, Emily P. https://orcid.org/0000-0001-5985-5714
Gaudet, Rachelle https://orcid.org/0000-0002-9177-054X
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA247069, R01CA208834)
Damon Runyon Cancer Research Foundation (DRG2369-19)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM120996)
- License Information
-
More Information
Article History
Received: 8 May 2021
Accepted: 12 August 2022
First Online: 17 October 2022
Competing interests
: E.P.B. and M.R.V. are listed as inventors on a provisional patent (US application 63/135,825) which relates to the methods and ClbP inhibitors described in Reference 22. The other authors declare no competing interests.
